Dicyclomine (Bentyl) – Case Study
Introduction
Dicyclomine (Bentyl) is a tertiary amine anticholinergic/antimuscarinic
antispasmodic agent used primarily to relieve gastrointestinal smooth
muscle spasms. It is commonly prescribed for irritable bowel syndrome (IBS)
and other functional bowel disorders. Dicyclomine relaxes gut muscle by
blocking muscarinic acetylcholine receptors (and also has a direct smooth-
muscle relaxant effect). It is marketed as both brand-name (Bentyl) and
generic formulations, and is available by prescription only. Dosage forms
include oral capsules (10 mg), tablets (20 mg), syrup (10 mg/5 mL), and an
intramuscular (IM) injectable solution.
Dicyclomine’s on-label indication is IBS with cramping, but it has been used
off-label for other spasmodic GI conditions. (Historically it was studied for
infant colic and peptic ulcer pain, but evidence is limited and safety concerns
in infants have curtailed those uses.) Its pharmacologic profile—a
combination of peripheral antimuscarinic action and direct musculotropic
smooth-muscle relaxation—makes it effective at reducing intestinal cramping
and pain in susceptible patients.
ADME Profile
Absorption
Bioavailability: Dicyclomine is well absorbed from the gastrointestinal tract.
Oral bioavailability is incomplete (roughly 67% relative to intramuscular
injection).
Onset and Peak: After an oral dose, onset of action is about 1–2 hours, with
peak plasma concentrations reached at 60–90 minutes. Onset may be
slightly faster after IM injection, but oral therapy is generally preferred if
feasible.
Formulations and Dosing: The usual adult dose is 10–20 mg four times daily,
with adjustment by patient response. A liquid oral solution and an IM
injection (10 mg/mL) are available for patients unable to take oral
medication. Because of relatively rapid absorption and onset, dicyclomine
can provide fairly quick symptom relief.
Distribution
Volume of Distribution (Vd): Dicyclomine has a large apparent volume of
distribution (~3.65 L/kg in adults), indicating extensive tissue penetration.
This widespread distribution allows the drug to reach sites of smooth muscle
throughout the body.
Protein Binding: Data on plasma protein binding are limited, but any highly
lipophilic tertiary amine would likely be moderately protein-bound (source
data are scarce).
Tissue Penetration: The large Vd and lipophilicity imply that dicyclomine
crosses the blood–brain barrier and the placenta. This is consistent with its
central anticholinergic side effects (e.g. confusion, hallucinations). It also
distributes to ocular and salivary tissues, producing effects like dry eyes and
mouth.
Metabolism
Hepatic Metabolism: The exact metabolic pathways of dicyclomine have not
been fully characterized. It is assumed to undergo hepatic metabolism
(likely by oxidative and hydrolytic pathways) as suggested by product
labeling and toxicology reviews. No specific cytochrome enzymes have been
definitively identified, and the drug’s metabolic fate remains poorly defined
in the literature.
Inactive Metabolites: Any metabolites are presumed to be inactive or
minimally active, as the parent drug is primarily responsible for
pharmacological effects.
Excretion
Renal Elimination: Dicyclomine is primarily eliminated in the urine.
Approximately 79–80% of an oral dose is recovered unchanged (or as
metabolites) in urine. About 8–10% is excreted via feces.
Half-life: Plasma concentrations decline in a biphasic manner. The initial
(alpha) half-life is relatively short, around 1.8 hours. There is also a longer
terminal (beta) half-life of roughly 9–10 hours in some studies. Because of
this multi-phasic elimination, complete drug effects may linger beyond the
initial peak.
Clearance: Specific clearance values are not well-documented, but with the
large Vd and dual-phase elimination, the overall clearance is substantial.
Patients with severe renal or hepatic impairment may experience prolonged
effects and should be dosed cautiously.
Side Effects
Common Side Effects
Dicyclomine’s adverse effects are largely those of a prototypical
anticholinergic agent. In clinical trials, over 60% of IBS patients reported
side effects. The most frequent side effects include:
Dry mouth and throat (xerostomia): Experienced by about one-third of
patients. This is due to blockade of salivary gland muscarinic receptors.
Dizziness: Occurs in roughly 40% of users. Patients may feel lightheaded or
unsteady, especially when rising quickly.
Blurred vision: Occurs in ~27%, often transient. Pupil dilation (mydriasis)
and loss of accommodation cause vision changes and light sensitivity.
Nausea and gastrointestinal discomfort: Some patients report nausea,
dyspepsia or constipation (anticholinergic slowing of GI motility). Mild
nausea was seen in ~14% of trial subjects.
Drowsiness or somnolence: About 9% of patients became unusually sleepy.
Fatigue and weakness are also reported anecdotally.
Other: Dicyclomine can cause headache, weakness, nervousness or
restlessness. These were seen in a minority of patients in trials.
In summary, common complaints are anticholinergic in nature: dry mouth,
blurred vision, dizziness, sedation/weakness, and occasional nausea or
constipation. These effects are usually mild-to-moderate and often diminish
with continued use or dose reduction.
Serious Adverse Effects
Though less frequent, serious side effects may occur, especially if the drug
accumulates or in susceptible individuals:
Central Nervous System: Marked confusion, delirium or hallucinations have
been reported, particularly in elderly or psychosis-prone patients.
Anticholinergics like dicyclomine can precipitate agitation, memory loss
(amnesia), disorientation and, rarely, seizure or coma in overdose. These
effects reflect CNS muscarinic blockade.
Cardiovascular: Tachycardia and palpitations may occur (due to blockade of
cardiac muscarinic receptors). In some cases, arrhythmias or hypertension
have been noted. Dicyclomine should be used cautiously in patients with
cardiac conditions.
Ophthalmic: Acute glaucoma (angle-closure) can be precipitated by pupillary
dilation; patients with narrow-angle glaucoma are at high risk. Blurred vision
is common, but acute painful glaucoma is a serious concern.
Urinary & GI: Urinary retention may occur, especially in men with prostate
enlargement. Anticholinergic blockade of bladder detrusor can make
urination difficult or impossible, sometimes requiring catheterization. Bowel
ileus or constipation can be severe in susceptible patients, and very rare
cases of Ogilvie’s syndrome (colonic pseudo-obstruction) have been
reported.
Heat Intolerance: Because sweating is inhibited, heat exhaustion or heat
stroke can occur if patients become overheated. Hot, flushed skin and a high
fever are warning signs of anticholinergic toxicity.
Allergic/Hypersensitivity: Rarely, angioedema or anaphylactic reactions may
occur.
Contraindications and Precautions
Contraindications: Dicyclomine should not be used in:
Infants <6 months: High risk of respiratory distress, seizures and death has
led to a black-box warning. Pediatric use is generally avoided.
Nursing Mothers: It is excreted in breast milk; nursing is contraindicated.
Unstable Cardiovascular Status: Acute hemorrhage or shock (anticholinergics
may worsen tachycardia).
Glaucoma: Especially narrow-angle or untreated glaucoma (risk of
precipitating acute attack).
Myasthenia Gravis: Anticholinergics can exacerbate muscle weakness.
Obstructive Uropathy: (e.g. benign prostatic hyperplasia with urinary
retention).
Obstructive GI Disease: (e.g. paralytic ileus, severe ulcerative colitis, toxic
megacolon). Anticholinergics may precipitate serious complications (toxic
dilation) in these settings.
Precautions: Use with caution in:
Elderly: Older adults are more sensitive to anticholinergic effects (confusion,
dizziness, falls) and have decreased clearance. MedlinePlus advises that
seniors “should not usually take dicyclomine” due to safety concerns.
Pediatric (6 mo – 2 yr): Even outside the <6mo range, infants and young
children risk severe respiratory and CNS effects. Dosing should be extremely
cautious or avoided.
Cardiac Conditions: Patients with arrhythmias, coronary artery disease or
tachycardia should use with caution.
Prostatic Hypertrophy: Risk of acute urinary retention warrants caution in
men with prostatic enlargement.
Hypertension, Hyperthyroidism: These states can be exacerbated by
anticholinergic-induced tachycardia.
Hot Environments or Fever: Patients should avoid overheating since
dicyclomine impairs sweating.
Advantages
Effective antispasmodic: Dicyclomine has demonstrated efficacy in IBS and
functional GI spasms. In controlled trials, 82% of IBS patients responded
favorably to dicyclomine (40 mg QID) versus 55% on placebo. It significantly
reduces abdominal pain, cramping and discomfort in many patients.
Rapid symptom relief: With a quick onset (≈1–2 hours) and peak at about 1
hour, dicyclomine can bring relatively prompt relief of cramps. Patients often
experience reduced GI cramping and urgency after a single dose.
Dual mechanism: Unlike pure parasympatholytics, dicyclomine also has
direct smooth-muscle relaxant effects. This musculotropic action
(independent of acetylcholine blockade) may enhance efficacy for spasm
relief.
Multiple dosage forms: Available as tablets, capsules, syrup and IM injection,
it offers flexibility. For instance, an IM dose can be used short-term when oral
therapy is not feasible (e.g. severe vomiting). This versatility is helpful in
acute care settings or for patients with swallowing difficulties.
Established safety profile (short-term): Dicyclomine is non-narcotic and
generally safe for short-term use. There is no known physical dependence
like with opioids. (Nonetheless, see Disadvantages for caveats on abuse
potential.)
Disadvantages
Anticholinergic side effects: The very properties that relax gut muscle also
cause unwanted effects. Dry mouth, blurred vision, constipation, sedation
and cognitive blunting can occur even at therapeutic doses. These effects
may limit tolerability, especially in sensitive individuals.
Elderly and pediatric limitations: Older adults are more prone to confusion,
falls and dehydration from dicyclomine. Children (especially infants) are at
risk of serious respiratory and neurological events. Thus, its use is restricted:
contraindicated under 6 months and generally not recommended in the
elderly or very young.
Frequent dosing: The short half-life (~1.8 h) necessitates 4-times-daily
dosing for sustained effect. This can be inconvenient and may affect
compliance.
Drug interactions: As an anticholinergic, it can interact adversely with other
CNS depressants, antipsychotics, or drugs that prolong QT (via tachycardia).
Caution is needed when used with other antimuscarinics (additive effects).
Rare abuse potential: Although uncommon, there are case reports of
dicyclomine misuse for its central anticholinergic/hallucinogenic effects.
Psychological dependence (not true craving) has been reported in a few
individuals seeking its euphoric or dissociative effects. This risk is very low
but should be acknowledged.
Contraindications restrict use: Many comorbid conditions (glaucoma, GI
obstruction, prostatic hypertrophy, etc.) outright forbid dicyclomine. These
restrictions limit its applicability compared to safer alternatives.
Reference:
1. [Link]
2011/[Link]?ref=0q_j95ix70nn-#:~:text=Absorption
%20and%20Distribution%20In%20man%2C,Elimination
2. [Link]
3. [Link]
%20PREFERRED%20TERM%20DICYCLOMINE
%20HYDROCHLORIDE,7%201%20Nervousness%206%202
4. [Link]
[Link]#:~:text=Dicyclomine%20is%20used%20to
%20treat,natural%20substance%20in%20the%20body
5. [Link]
%20effectiveness%20of%20Bentyl%20,cholinergic%20activity%20of
%20the
